BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho HM, Lee KH, Shen YM, Shin TJ, Ryu PD, Choi MC, Kang KS, Cho JY. Transplantation of hMSCs Genome Edited with LEF1 Improves Cardio-Protective Effects in Myocardial Infarction. Mol Ther Nucleic Acids. 2020;19:1186-1197. [PMID: 32069701 DOI: 10.1016/j.omtn.2020.01.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Bassawon R, Khan K, Siddique A, Shum-tim D. Genome Editing and Cardiac Regeneration. Advances in Experimental Medicine and Biology 2023. [DOI: 10.1007/978-981-19-5642-3_3] [Reference Citation Analysis]
2 Hazrati A, Malekpour K, Soudi S, Hashemi SM. CRISPR/Cas9-engineered mesenchymal stromal/stem cells and their extracellular vesicles: A new approach to overcoming cell therapy limitations. Biomedicine & Pharmacotherapy 2022;156:113943. [DOI: 10.1016/j.biopha.2022.113943] [Reference Citation Analysis]
3 Huang Y, Wang B. Strategies and applications of cell surface engineering. Sci Sin -Vitae 2022. [DOI: 10.1360/ssv-2022-0067] [Reference Citation Analysis]
4 Chetty S, Yarani R, Swaminathan G, Primavera R, Regmi S, Rai S, Zhong J, Ganguly A, Thakor AS. Umbilical cord mesenchymal stromal cells—from bench to bedside. Front Cell Dev Biol 2022;10:1006295. [DOI: 10.3389/fcell.2022.1006295] [Reference Citation Analysis]
5 Dong M, Liu J, Liu C, Wang H, Sun W, Liu B. CRISPR/CAS9: A promising approach for the research and treatment of cardiovascular diseases. Pharmacol Res 2022;:106480. [PMID: 36191879 DOI: 10.1016/j.phrs.2022.106480] [Reference Citation Analysis]
6 Li S, Tang H, Li C, Ma J, Ali M, Dong Q, Wu J, Hui Y, Sun C. Synthetic Biology Technologies And Genetically Engineering Strategies For Enhanced Cell Therapeutics. Stem Cell Rev Rep 2022. [PMID: 36166137 DOI: 10.1007/s12015-022-10454-5] [Reference Citation Analysis]
7 Raziyeva K, Kim Y, Zharkinbekov Z, Temirkhanova K, Saparov A. Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction. Biomedicines 2022;10:2178. [DOI: 10.3390/biomedicines10092178] [Reference Citation Analysis]
8 Vastrad B, Vastrad C. Comprehensive analysis of next-generation sequencing data in COVID-19 and its secondary complications.. [DOI: 10.1101/2022.02.03.478930] [Reference Citation Analysis]
9 Chattopadhyaya S, Czubryt MP. Gene Therapy and Its Application in Cardiac Diseases. Biochemistry of Apoptosis and Autophagy 2022. [DOI: 10.1007/978-3-030-78799-8_8] [Reference Citation Analysis]
10 Guo N, Liu J, Li W, Ma Y, Fu D. The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy. Journal of Advanced Research 2021. [DOI: 10.1016/j.jare.2021.11.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Yousefi-ahmadipour A, Asadi F, Pirsadeghi A, Nazeri N, Vahidi R, Abazari MF, Afgar A, Mirzaei-parsa MJ. Current Status of Stem Cell Therapy and Nanofibrous Scaffolds in Cardiovascular Tissue Engineering. Regen Eng Transl Med . [DOI: 10.1007/s40883-021-00230-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kim Y, Zharkinbekov Z, Sarsenova M, Yeltay G, Saparov A. Recent Advances in Gene Therapy for Cardiac Tissue Regeneration. Int J Mol Sci 2021;22:9206. [PMID: 34502115 DOI: 10.3390/ijms22179206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Rahimnejad M, Nasrollahi Boroujeni N, Jahangiri S, Rabiee N, Rabiee M, Makvandi P, Akhavan O, Varma RS. Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering. Nanomicro Lett 2021;13:182. [PMID: 34409511 DOI: 10.1007/s40820-021-00697-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
14 Siew WS, Tang YQ, Kong CK, Goh BH, Zacchigna S, Dua K, Chellappan DK, Duangjai A, Saokaew S, Phisalprapa P, Yap WH. Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications. Int J Mol Sci 2021;22:8422. [PMID: 34445123 DOI: 10.3390/ijms22168422] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Kolur V, Vastrad B, Vastrad C, Kotturshetti S, Tengli A. Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis. BMC Cardiovasc Disord 2021;21:329. [PMID: 34218797 DOI: 10.1186/s12872-021-02146-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
16 Maganti HB, Bailey AJM, Kirkham AM, Shorr R, Pineault N, Allan DS. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies. Stem Cells Transl Med 2021;10:996-1007. [PMID: 33666363 DOI: 10.1002/sctm.20-0520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Denu RA, Hematti P. Optimization of oxidative stress for mesenchymal stromal/stem cell engraftment, function and longevity. Free Radic Biol Med 2021;167:193-200. [PMID: 33677063 DOI: 10.1016/j.freeradbiomed.2021.02.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Vastrad B, Tengli A, Vastrad C. Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis.. [DOI: 10.1101/2021.01.24.428028] [Reference Citation Analysis]
19 Cho HM, Cho JY. Cardiomyocyte Death and Genome-Edited Stem Cell Therapy for Ischemic Heart Disease. Stem Cell Rev Rep 2021;17:1264-79. [PMID: 33492627 DOI: 10.1007/s12015-020-10096-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Um S, Ha J, Choi SJ, Oh W, Jin HJ. Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells. World J Stem Cells 2020; 12(12): 1511-1528 [PMID: 33505598 DOI: 10.4252/wjsc.v12.i12.1511] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
21 Deng J, Zhang N, Wang Y, Yang C, Wang Y, Xin C, Zhao J, Jin Z, Cao F, Zhang Z. FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction. Stem Cell Res Ther 2020;11:228. [PMID: 32522253 DOI: 10.1186/s13287-020-01746-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]